Contact the Roche Precision  Medicine Partner in your area

How would you like to be contacted?

We aim to get in touch within one business day

Disclaimer:  I consent to my data being processed for the purpose of responding to my inquiry and in accordance with the Roche Global Privacy Policy & Privacy Notice for Pharmacovigilance

Bring the potential of ROZLYTREK® to life

ROZLYTREK

offers convenient

once-daily,

oral dosing1

ROZLYTREK offers convenient once-daily, oral dosing1

  • The recommended dose for adults is 600 mg orally once-daily
  • ROZLYTREK can be taken with or without food

ROZLYTREK dosing

Dosing

Pills
Food
  • Adults: Recommended dose is 600 mg orally once-daily
  • Children 12 years and over: Recommended dose is 300 mg/m2 orally once-daily for those who can swallow whole capsules
  • Available in 100 mg and 200 mg hard capsules
  • Can be taken with or without food
    • No significant effect of food on bioavailability was observed

Paediatric dosing1

Body surface area 1.11-1.50m2 Once-daily does 400 mg, 1.51m2 or more 600 mg

ROZLYTREK dosing modifications

 

Temporary interruption, dose reduction or discontinuation of treatment with ROZLYTREK may help manage adverse reactions1

 

Dose Reduction Schedule of ROZLYTREK for Paediatric Patients BSA of 1.11 m2 to 1.50 m2
Starting Dose
400 mg once-daily
 
First Reduction
300 mg once-daily
Second Reduction
200 mg, for 5 days each week
(Monday, Wednesday, Friday, Saturday, Sunday)
  • ROZLYTREK should be permanently discontinued if patients are unable to tolerate the lowest reduced rate
Dose Reduction Schedule of ROZLYTREK for Adult Patients and Paediatric Patients BSA ≥ 1.51 m2
Starting Dose
600 mg once-daily
 
First Reduction
400 mg once-daily
Second Reduction
400 mg once-daily
  • ROZLYTREK should be permanently discontinued if patients are unable to tolerate the lowest reduced rate
Does Reduction for Specific Adverse Reactions

ROZLYTREK SmPC

Download the ROZLYTREK Summary of Product Characteristics

To read the full product information:

Download SmPC

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for details on how to report adverse reactions.

Footnotes

ALT, alanine aminotransferase; AR, adverse reaction; AST, aspartate aminotransferase; BSA, body surface area; ms, millisecond; QT, time from the start of the Q wave to the end of the T wave; QTc, the corrected QT interval; SmPC, summary of product characteristics; ULN, upper limit of normal.

References

  1. ROZLYTREK Summary of Product Characteristics, 2020.